AR092316A1 - Composiciones - Google Patents
ComposicionesInfo
- Publication number
- AR092316A1 AR092316A1 ARP130101497A ARP130101497A AR092316A1 AR 092316 A1 AR092316 A1 AR 092316A1 AR P130101497 A ARP130101497 A AR P130101497A AR P130101497 A ARP130101497 A AR P130101497A AR 092316 A1 AR092316 A1 AR 092316A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino acid
- tyrosine
- cysteine
- leucine
- arginine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composición que comprende por lo menos un mimótopo de un epítopo del péptido b amiloide (Ab) para utilizar en la prevención y/o tratamiento de las sinucleinopatías y/o mejora de los síntomas motores y/o cognitivos de las sinucleopatías, donde dicho por lo menos un mimótopo está acoplado o fusionado a una proteína portadora farmacéuticamente aceptable seleccionada entre el grupo que consiste en un mutante no tóxico de la toxina de la difteria, hemocianina de lapa californiana (KLH), toxina de la difteria (DT), toxoide tetánico (TT) y proteína D de Haemophilus influenzae (proteína D). Reivindicación 8: La composición según cualquiera de las reivindicaciones 1 a 7, donde el por lo menos un mimótopo comprende la secuencia de aminoácidos: X¹X²X³X⁴X⁵X⁶X⁷ donde X¹ es G o un aminoácido con un grupo hidroxi o un aminoácido cargado negativamente, preferentemente glicina (G), ácido glutámico (E), tirosina (Y), Serina (S) o ácido aspártico (D), X² es un aminoácido hidrófobo o un aminoácido cargado positivamente, preferentemente asparagina (N), isoleucina (I), leucina (L), valina (V), lisina (K), triptófano (W), arginina (R), tirosina (Y), fenilalanina (F) o alanina (A), X³ es un aminoácido cargado negativamente, preferentemente ácido aspártico (D) o ácido glutámico (E), X⁴ es un aminoácido aromático o un aminoácido hidrófobo o leucina (L), preferentemente tirosina (Y), fenilalanina (F) o leucina (L), X⁵ es histidina (H), lisina (K), tirosina (Y), fenilalanina (F) o arginina (R), preferentemente histidina (H), fenilalanina (F) o arginina (R), y X⁶ no está presente o serina (S), treonina (T), asparagina (N), glutamina (Q), ácido aspártico (D), ácido glutámico (E), arginina (R), isoleucina (I), lisina (K), tirosina (Y), o glicina (G), preferentemente treonina (T), asparagina (N), ácido aspártico (D), arginina (R), isoleucina (I) o glicina (G), X⁷ no está presente o es cualquier aminoácido, preferentemente prolina (P), tirosina (Y), treonina (T), glutamina (Q), alanina (A), histidina (H) o serina (S); preferentemente EIDYHR, ELDYHR, EVDYHR, DIDYHR, DLDYHR, DVDYHR, Dl-DYRR, DLDYRR, DVDYRR, DKELRI, DWELRI, YREFFI, YREFRI, YAEFRG, EAEFRG, DYEFRG, ELEFRG, DRELRI, DKELKI, DRELKI, GREFRN, EYEFRG, DWEFRDA, SWEFRT, DKELR, SFEFRG, DAEFRWP, DNEFRSP, GSEFRDY, GAEFRFT, SAEFRTQ, SAEFRAT, SWEFRNP, SWEFRLY, SWELRQA, SVEFRYH, SYEFRHH, SQEFRTP, SSEFRVS, DWEFRD, DAELRY, DWELRQ, SLEFRF, GPEFRW, GKEFRT, AYEFRH, DKE(Nle)R, DKE(Nva)R o DKE(Cha)R. Reivindicación 9: La composición según cualquiera de las reivindicaciones 1 a 7, donde el por lo menos un mimótopo comprende la secuencia de aminoácidos: X¹RX²DX³(X⁴)ₙ(X⁵)ₘ(X⁶)ₒ donde X¹ es isoleucina (I) o valina (V), X² es triptofano (W) o tirosina (Y), X³ es treonina (T), valina (V), alanina (A), metionina (M), glutamina (Q) o glicina (G), X⁴ es prolina (P), alanina (A), tirosina (Y), serina (S), cisteína (C) o glicina (G), X⁵ es prolina (P), leucina (L), glicina (G) o cisteína (C), X⁶ es cisteína (C), n, m y o son, independientemente, 0 ó 1; preferentemente IRWDTP(C), VRWDVYP(C), IRYDAPL(C), IRYDMAG(C), IRWDTSL(C), IRWDQP(C), IRWDG(C) o IRWDGG(C). Reivindicación 10: La composición según cualquiera de las reivindicaciones 1 a 7, donde el por lo menos un mimótopo comprende la secuencia de aminoácidos: EX¹WHX²X³(X⁴)ₙ(X⁵)ₘ donde X¹ es valina (V), arginina (R) o leucina (L), X² es arginina (R) o ácido glutámico (E), X³ es alanina (A), histidina (H), lisina (K), leucina (L), tirosina (Y) o glicina (G), X⁴ es prolina (P), histidina (H), fenilalanina (E) o glutamina (Q) o cisteína (C), X⁵ es cisteína (C), n y m son, independientemente, 0 ó 1; preferentemente EVWHRHQ(C), ERWHEKH(C), EVWHRLQ(C), ELWHRYP(C), ELWHRAF(C), ELWHRA(C), EVWHRG(C), EVWHRH(C) y ERWHEK(C), preferentemente EVWHRHQ(C), ERWHEKH(C), EVWHRLQ(C), ELWHRYP(C) o ELWHRAF(C). Reivindicación 12: La composición según cualquiera de las reivindicaciones 1 a 7, donde el por lo menos un mimótopo comprende la secuencia de aminoácidos: (X¹ᵃ)ₘGX²ᵃX³ᵃX⁴ᵃFX⁵ᵃX⁶ᵃ(X⁷ᵃ)ₙ donde X¹ᵃ es serina (S), alanina (A) o cisteína (C), X²ᵃ es serina (S), treonina (T), ácido glutámico (E), ácido aspártico (D), glutamina (Q) o metionina (M), X³ᵃ es isoleucina (1), tirosina (Y), metionina (M) o leucina (L), X⁴ᵃ es leucina (L), arginina (R), glutamina (Q), triptofano (W), valina (V), histidina (H), tirosina (Y), isoleucina (I), lisina (K) metionina (M) o fenilalanina (F), X⁵ᵃ es alanina (A), fenilalanina (F), histidina (H), asparagina (N), arginina (R), ácido glutámico (E), isoleucina (I), glutamina (Q), ácido aspártico (D), prolina (P) o triptofano (W),glicina (G), X⁶ᵃ es cualquier residuo de aminoácido, X⁷ᵃ es cisteína (C), m y n son, independientemente, 0 ó 1; preferentemente SGEYVFH(C), SGQLKFP(C), SGQIWFR(C), SGEIHFN(C), GQIWFIS(C), GQIIFQS(C), GQIRFDH(C), GEMWFAL(C), GELQFPP(C), GELWFP(C), GEMQFFI(C), GELYFRA(C), GEIRFAL(C), GMIVFPH(C), GEIWFEG(C), GDLKFPL(C), GQILFPV(C), GELFFPK(C), GQIMFPR(C), GSLFFWP(C), GEILFGM(C), GQLKFPF(C), GTIFFRD(C), GQIKFAQ(C), GTLIFHH(C), GEIRFGS(C), GQIQFPL(C), GEIKFDH(C), GEIQFGA(C), GELFFEK(C), GEIRFEL(C), GEIYFER(C), SGEIYFER(C), AGEIYFER(C) o (C)GEIYFER. Reivindicación 13: La composición según cualquiera de las reivindicaciones 1 a 7, donde el por lo menos un mimótopo comprende la secuencia de aminoácidos: (X¹ᵇ)ₘHX²ᵇX³ᵇX⁴ᵇX⁵ᵇFX⁶ᵇ(X⁷ᵇ)ₙ donde X¹ᵇ es serina (S), treonina (T) o cisteína (C), X²ᵇ es glutamina (Q), treonina (T) o metionina (M), X³ᵇ es lisina (K) o arginina (R), X⁴ᵇ es leucina (L), metionina (M), X⁵ᵇ es triptofano (W), tirosina (Y), fenilalanina (F) o isoleucina (1), X⁶ᵇ es asparagina (N), ácido glutámico (E), alanina (A) o cisteína (C), X⁷ᵇ es cisteína (C), n y m son, independientemente, 0 ó 1; preferentemente SHTRLYF(C), HMRLFFN(C), SHQRLWF(C), HQKMIFA(C), HMRMYFE(C), THQRLWF(C) o HQKMIF(C). Reivindicación 16: La composición según cualquiera de las reivindicaciones 1 a 15, donde el por lo menos un mimótopo se selecciona entre el grupo de DKELRI, SWEFRT, SEFKHG, ILFRHG, TLHEFRH, GAEFRFT, DWEFRD, SLEFRF, GREFRN, IRWDTP y HQKMIFA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12166316.5A EP2659908A1 (en) | 2012-05-01 | 2012-05-01 | Compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
AR092316A1 true AR092316A1 (es) | 2015-04-15 |
Family
ID=48407469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130101497A AR092316A1 (es) | 2012-05-01 | 2013-05-02 | Composiciones |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2659908A1 (es) |
AR (1) | AR092316A1 (es) |
TW (1) | TW201345927A (es) |
WO (1) | WO2013164357A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015165961A1 (en) * | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
CA2946929A1 (en) * | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
CA3004498A1 (en) | 2015-11-09 | 2017-05-18 | Neil R. Cashman | Amyloid beta epitopes and antibodies thereto |
KR20180085736A (ko) | 2015-11-09 | 2018-07-27 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아밀로이드 베타 중간-영역 내 에피토프 및 이에 대해 구조적으로 선택성인 항체 |
JP2019533426A (ja) | 2016-07-18 | 2019-11-21 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | アミロイドベータに対する抗体 |
US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
CN108676072B (zh) * | 2018-05-24 | 2021-05-14 | 华南理工大学 | 一种具有抗Aβ42蛋白聚集功能的多肽及其应用与编码该多肽的基因 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0114787B1 (de) | 1983-01-25 | 1991-09-25 | Ciba-Geigy Ag | Neue Peptidderivate |
GB8815795D0 (en) | 1988-07-02 | 1988-08-10 | Bkl Extrusions Ltd | Glazing bead |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
UA40597C2 (uk) | 1992-06-25 | 2001-08-15 | Смітклайн Бічем Байолоджікалс С.А. | Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів |
ES2162139T5 (es) | 1993-03-23 | 2008-05-16 | Smithkline Beecham Biologicals S.A. | Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado. |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
AUPO517897A0 (en) | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
AU1145699A (en) | 1997-09-05 | 1999-03-22 | Smithkline Beecham Biologicals (Sa) | Oil in water emulsions containing saponins |
US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
EP1069910A1 (en) | 1998-04-09 | 2001-01-24 | GlaxoSmithKline Biologicals S.A. | Adjuvant compositions |
NZ513935A (en) | 1999-02-17 | 2004-02-27 | Csl Ltd | Immunogenic complexes and methods relating thereto |
KR20020038770A (ko) | 1999-09-24 | 2002-05-23 | 장 스테판느 | 애쥬번트로서의 폴리옥시에틸렌 소르비탄 에스테르와옥톡시놀의 조합물의 용도 및 백신과 관련된 이의 용도 |
CO5200838A1 (es) | 1999-09-24 | 2002-09-27 | Smithkline Beecham Corp | Vacunas |
AU2002357007A1 (en) | 2001-11-21 | 2003-06-10 | New York University | SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID Beta, PRION PROTEIN, AMYLIN, Alpha-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO |
TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
US8697082B2 (en) | 2002-11-01 | 2014-04-15 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
PT1633189T (pt) | 2003-05-19 | 2017-10-04 | Prothena Biosciences Ltd | Fragmentos truncados de alfa-sinucleína em doença com corpos de lewy |
JPWO2004113535A1 (ja) | 2003-06-22 | 2007-09-20 | 早出 広司 | 凝集抑制作用を有するシヌクレイン変異体 |
AT413946B (de) | 2004-07-13 | 2006-07-15 | Mattner Frank Dr | Impfstoff gegen die alzheimer-krankheit |
AU2005333126A1 (en) | 2004-07-18 | 2006-12-21 | Csl Limited | Methods and compositions for inducing innate immune responses |
EP1781325A2 (en) | 2004-07-18 | 2007-05-09 | CSL Limited | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯 |
JP5356228B2 (ja) | 2006-07-07 | 2013-12-04 | ギリアード サイエンシーズ, インコーポレイテッド | toll様レセプター7の調節因子 |
PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
JP5380465B2 (ja) | 2008-03-03 | 2014-01-08 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Tlr活性モジュレーターとしての化合物および組成物 |
SI2276486T1 (sl) | 2008-03-24 | 2014-01-31 | 4Sc Discovery Gmbh | Novi substituirani imidazokinolini |
AT506820B1 (de) | 2008-06-12 | 2011-07-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzine gegen alzheimer-krankheit |
AT506819B1 (de) | 2008-06-12 | 2011-06-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzin zur behandlung von alzheimer-krankheit |
MX2010013647A (es) | 2008-06-12 | 2011-04-05 | Affiris Ag | Compuestos para tratar sintomas asociados con la enfermedad de parkinson. |
AU2009276403B2 (en) | 2008-08-01 | 2016-03-10 | Ventirx Pharmaceuticals, Inc. | Toll-like receptor agonist formulations and their use |
-
2012
- 2012-05-01 EP EP12166316.5A patent/EP2659908A1/en not_active Withdrawn
-
2013
- 2013-04-30 WO PCT/EP2013/059029 patent/WO2013164357A1/en active Application Filing
- 2013-05-01 TW TW102115611A patent/TW201345927A/zh unknown
- 2013-05-02 AR ARP130101497A patent/AR092316A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP2659908A1 (en) | 2013-11-06 |
TW201345927A (zh) | 2013-11-16 |
WO2013164357A1 (en) | 2013-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR092316A1 (es) | Composiciones | |
ES2531541T3 (es) | Agentes de unión del receptor Notch1 y procedimientos de uso de los mismos | |
NZ712148A (en) | Wt1 antigen peptide conjugate vaccine | |
AR125326A2 (es) | Composiciones de neisseria meningitidis y métodos de las mismas | |
RU2011100125A (ru) | Соединения для лечения амилоидозов | |
RU2011100126A (ru) | Применение мимотопов для лечения бетта-амилоидозов | |
AR105616A1 (es) | Proteínas de fusión | |
HRP20160594T1 (hr) | Uporaba mimotopa od alfa-sinuklein epitopa za liječenje bolesti s lewyjevim tijelima | |
JP2015511603A5 (es) | ||
RU2016140627A (ru) | Бета-лактамазы с улучшенными свойствами для лечения | |
MY159464A (en) | Reconstituted surfactant composition containing analogs of surfactant protein b (sp-b) and surfactant protein c (sp-c) | |
ATE532795T1 (de) | Tumor-assoziiertes peptid, welches an unterschiedliche menschliche leukozytenantigene der klasse ii bindet | |
SI3042917T1 (en) | PROTITELES AGAINST N3PGL AMILOID BETA PEPTID AND THEIR APPLICATION | |
DOP2009000167A (es) | Vacuna | |
MY191490A (en) | Vaccine against porcine parvovirus | |
PE20191711A1 (es) | Peptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cancer | |
RU2015110981A (ru) | Комбинации и их применение | |
WO2013020722A3 (en) | Composition comprising small peptide as amyloid beta mimotope and adjuvant for use as vaccine against alzheimer's disease | |
AR090439A1 (es) | Lipopeptidos antimicrobianos cortos | |
NZ629843A (en) | Identification of channelrhodopsin-2 (chop2) mutations and methods of use | |
RU2014114506A (ru) | Вакцина | |
AR090917A1 (es) | Composiciones | |
IN2014DN08325A (es) | ||
AR095386A1 (es) | Péptidos de kntc2 y vacunas que los contienen | |
EA201492068A1 (ru) | Гидрохлоридная соль пептида и ее применение в комбинации с другими пептидами в иммунотерапии |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |